Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
Background PD1 immune checkpoint blockade (αPD1 ICB) has shown unparalleled success in treating many types of cancer. However, response to treatment does not always lead to tumor rejection. While αPD1 ICB relies on cytotoxic CD8+ T cells, antigen-presenting cells (APCs) at the tumor site are also ne...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000588.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846172568591007744 |
|---|---|
| author | Louis Boon Matheus H W Crommentuijn Sjoerd T T Schetters Laura J W Kruijssen Yvette van Kooyk Ernesto Rodriguez Jan Van den Bossche Joke M M Den Haan |
| author_facet | Louis Boon Matheus H W Crommentuijn Sjoerd T T Schetters Laura J W Kruijssen Yvette van Kooyk Ernesto Rodriguez Jan Van den Bossche Joke M M Den Haan |
| author_sort | Louis Boon |
| collection | DOAJ |
| description | Background PD1 immune checkpoint blockade (αPD1 ICB) has shown unparalleled success in treating many types of cancer. However, response to treatment does not always lead to tumor rejection. While αPD1 ICB relies on cytotoxic CD8+ T cells, antigen-presenting cells (APCs) at the tumor site are also needed for costimulation of tumor-infiltrating lymphocytes (TILs). It is still unclear how these APCs develop and function before and during αPD1 ICB or how they are associated with tumor rejection.Methods Here, we used B16 mouse melanoma and MC38 colorectal carcinoma tumor models, which show differential responses to αPD1 ICB. The immune composition of ICB insensitive B16 and sensitive MC38 were extensively investigated using multi-parameter flow cytometry and unsupervised clustering and trajectory analyses. We additionally analyzed existing single cell RNA sequencing data of the myeloid compartment of patients with melanoma undergoing αPD1 ICB. Lastly, we investigated the effect of CD40 agonistic antibody on the tumor-infiltrating monocyte-derived cells during αPD1 ICB.Results We show that monocyte-derived dendritic cells (moDCs) express high levels of costimulatory molecules and are correlated with effector TILs in the tumor microenvironment (TME) after αPD1 ICB only in responding mouse tumor models. Tumor-resident moDCs showed distinct differentiation from monocytes in both mouse and human tumors. We further confirmed significant enrichment of tumor-resident differentiated moDCs in patients with melanoma responding to αPD1 ICB therapy compared with non-responding patients. Moreover, moDCs could be targeted by agonistic anti-CD40 antibody, supporting moDC differentiation, effector T-cell expansion and anti-tumor immunity.Conclusion The combined analysis of myeloid and lymphoid populations in the TME during successful and non-successful PD1 ICB led to the discovery of monocyte-to-DC differentiation linked to expanding T-cell populations. This differentiation was found in patients during ICB, which was significantly higher during successful ICB. The finding of tumor-infiltrating monocytes and differentiating moDCs as druggable target for rational combination therapy opens new avenues of anti-tumor therapy design. |
| format | Article |
| id | doaj-art-0b3a381377d2418f88931130ae98ba49 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-0b3a381377d2418f88931130ae98ba492024-11-10T00:10:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-10-018210.1136/jitc-2020-000588Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapyLouis Boon0Matheus H W Crommentuijn1Sjoerd T T Schetters2Laura J W Kruijssen3Yvette van Kooyk4Ernesto Rodriguez5Jan Van den Bossche6Joke M M Den Haan72 Polpharma Biologics, Utrecht, The NetherlandsDepartment of Molecular Cell Biology and Immunology, Amsterdam Infection & Immunity Institute and Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The NetherlandsDepartment of Molecular Cell Biology and Immunology, Amsterdam Infection & Immunity Institute and Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The NetherlandsDepartment of Molecular Cell Biology and Immunology, Amsterdam Infection & Immunity Institute and Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The NetherlandsMolecular Cell Biology & Immunology, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The NetherlandsMolecular Cell Biology & Immunology, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands1 Molecular Cell Biology and Immunology, Amsterdam Institute for Infection and Immunity, Cancer Center Amsterdam, Amsterdam UMC - Location VUMC, Amsterdam, The NetherlandsMolecular Cell Biology & Immunology, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The NetherlandsBackground PD1 immune checkpoint blockade (αPD1 ICB) has shown unparalleled success in treating many types of cancer. However, response to treatment does not always lead to tumor rejection. While αPD1 ICB relies on cytotoxic CD8+ T cells, antigen-presenting cells (APCs) at the tumor site are also needed for costimulation of tumor-infiltrating lymphocytes (TILs). It is still unclear how these APCs develop and function before and during αPD1 ICB or how they are associated with tumor rejection.Methods Here, we used B16 mouse melanoma and MC38 colorectal carcinoma tumor models, which show differential responses to αPD1 ICB. The immune composition of ICB insensitive B16 and sensitive MC38 were extensively investigated using multi-parameter flow cytometry and unsupervised clustering and trajectory analyses. We additionally analyzed existing single cell RNA sequencing data of the myeloid compartment of patients with melanoma undergoing αPD1 ICB. Lastly, we investigated the effect of CD40 agonistic antibody on the tumor-infiltrating monocyte-derived cells during αPD1 ICB.Results We show that monocyte-derived dendritic cells (moDCs) express high levels of costimulatory molecules and are correlated with effector TILs in the tumor microenvironment (TME) after αPD1 ICB only in responding mouse tumor models. Tumor-resident moDCs showed distinct differentiation from monocytes in both mouse and human tumors. We further confirmed significant enrichment of tumor-resident differentiated moDCs in patients with melanoma responding to αPD1 ICB therapy compared with non-responding patients. Moreover, moDCs could be targeted by agonistic anti-CD40 antibody, supporting moDC differentiation, effector T-cell expansion and anti-tumor immunity.Conclusion The combined analysis of myeloid and lymphoid populations in the TME during successful and non-successful PD1 ICB led to the discovery of monocyte-to-DC differentiation linked to expanding T-cell populations. This differentiation was found in patients during ICB, which was significantly higher during successful ICB. The finding of tumor-infiltrating monocytes and differentiating moDCs as druggable target for rational combination therapy opens new avenues of anti-tumor therapy design.https://jitc.bmj.com/content/8/2/e000588.full |
| spellingShingle | Louis Boon Matheus H W Crommentuijn Sjoerd T T Schetters Laura J W Kruijssen Yvette van Kooyk Ernesto Rodriguez Jan Van den Bossche Joke M M Den Haan Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy Journal for ImmunoTherapy of Cancer |
| title | Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy |
| title_full | Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy |
| title_fullStr | Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy |
| title_full_unstemmed | Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy |
| title_short | Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy |
| title_sort | monocyte derived apcs are central to the response of pd1 checkpoint blockade and provide a therapeutic target for combination therapy |
| url | https://jitc.bmj.com/content/8/2/e000588.full |
| work_keys_str_mv | AT louisboon monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy AT matheushwcrommentuijn monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy AT sjoerdttschetters monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy AT laurajwkruijssen monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy AT yvettevankooyk monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy AT ernestorodriguez monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy AT janvandenbossche monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy AT jokemmdenhaan monocytederivedapcsarecentraltotheresponseofpd1checkpointblockadeandprovideatherapeutictargetforcombinationtherapy |